Asia-Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. Rising incidences of diabetes is the major factor accelerating market growth. As per the Asian Diabetes Prevention Initiative, 60% of the diabetic population across the globe live in Asia. In China, total cases of diabetes in adults was nearly 116.4 million in 2019, while in India, it was nearly 77 million in 2019. The most common diabetic complication is peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. This condition affects the legs and feet first and is followed by hands and arms. Several prescription medications are available for diabetes-associated nerve pain. Some antidepressants provide ease to nerve pain. Tricyclic antidepressants may support mild to moderate nerve pain. This class of drugs includes imipramine (Tofranil), amitriptyline, and desipramine (Norpramin).
Asia-Pacific peripheral neuropathy treatment market is segmented based on type and application. Based on type, the market is classified into antidepressants, pain relievers, antiseizure, and others. Based on the application, the market is classified into diabetes, chemotherapy-induced, and others. Increasing cancer prevalence is resulting in an increasing demand for chemotherapy in the region. As per the World Health Organization (WHO), in 2018, the number of new cancer incidences reported in the South-East Asia region was nearly 2 million. This results in an increasing demand for chemotherapy which is most often used for cancer treatment. Chemotherapy may lead to the degeneration of motor nerves and peripheral sensory. It has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. Chemotherapy-induced peripheral neuropathy is normally treated with analgesics, antidepressants, and anticonvulsants.
To Request a Sample of our Asia-Pacific Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment-market
Asia-Pacific Peripheral Neuropathy Treatment Market-Segmentation
By Type
- Antidepressants
- Pain Relievers
- Antiseizure
- Others
By Application
- Diabetes
- Chemotherapy-Induced
- Others
A full Report of Asia-Pacific Peripheral Neuropathy Treatment Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-peripheral-neuropathy-treatment-market
Regional Analysis
- China
- India
- Japan
Rest of Asia-Pacific
Company Profiles
- Alembic Pharmaceuticals Ltd.
- Bristol Myers Squibb Co.
- Cipla Ltd.
- Daiichi Sankyo Company, Ltd.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Lupin, Ltd.
- Mylan N.V.
- Novartis International AG
- Pfizer, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-peripheral-neuropathy-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
